The Secretary of Health (SOH) approved the HTAC recommendation on April 21 to finance a fourth dose of COVID-19 Vaccines AstraZeneca, CoronaVac, Moderna, Pfizer-BioNTech, and Sinopharm among the immunocompromised population (ICPs) ages 18 years old and above given at least 3 months after the third dose, and include these vaccines in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP). While continue reading : Fourth Dose of COVID-19 Vaccines Among the Immunocompromised Population (ICPs)
Pfizer-BioNTech (10ug/dose) COVID-19 Vaccine for Children 5 to 11 Years Old
Evidence Summary: Document Link
Covovax for the Prevention of COVID-19
Date of publication: December 14, 2021 Decision of the Secretary of Health: Approved (24 December 2021) Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the continue reading : Covovax for the Prevention of COVID-19
Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the Prevention of COVID-19 (December Reassessment)
Date of publication: December 14, 2021 Decision of the Secretary of Health: Approved (24 December 2021) Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the continue reading : Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the Prevention of COVID-19 (December Reassessment)
COVID-19 Vaccine Sinopharm for the Prevention of COVID-19
Date of publication: November 29, 2021 Decision of the Secretary of Health: Approved (03 December 2021) Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the continue reading : COVID-19 Vaccine Sinopharm for the Prevention of COVID-19